Dergiler / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 6

The concentration of interleukin-33 in heart failure with reduced ejection fraction

Sayfa
305–313
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In addition, interleukin concentrations varied depending on the etiology and severity of the course of the disease. (Anatol J Cardiol 2019; 21: 305-13)

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Despite several improvements in the management of heart failure (HF), it is still an incurable and a progressive disease.
📊
Temel Bulgular & Veri:Several trials demonstrated that the process of inflammation may be responsible for initiation and progression of HF.
💡
Sonuç & Katkı:In addition, interleukin concentrations varied depending on the etiology and severity of the course of the disease. (Anatol J Cardiol 2019; 21: 305-13)
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Despite several improvements in the management of heart failure (HF), it is still an incurable and a progressive disease. Several trials demonstrated that the process of inflammation may be responsible for initiation and progression of HF. The aim of the present study was to investigate the role of interleukin-33 (IL-33) in the pathogenesis of HF and to assess whether disease etiology and course of the disease affect the expression of cytokines.Methods: The study included 155 (106 male and 49 female) patients with systolic HF with a mean left ventricle ejection fraction of 32.13±12.8% and 60 (36 male and 24 female) healthy individuals. IL-33 concentrations were evaluated using enzyme-linked immunosorbent assay.Results: The concentration of IL-33 was statistically significantly lower in patients with HF than in healthy subjects, 16.91 (0–81.00) pg/mL and 92.51 (33.61–439.61) pg/mL, respectively. Patients with HF with ischemic etiology had lower concentration of IL-33 (10.75 pg/mL) than subjects with HF with non-ischemic etiology (21.05 pg/mL). Patients with stable HF (10.46 pg/mL) had lower IL-33 levels than those with unstable HF (19.02 pg/mL).Conclusion: The concentrations of IL-33 were lower in patients with HF than in healthy controls, which may play an important role of above cytokine in HF development and progression. In addition, interleukin concentrations varied depending on the etiology and severity of the course of the disease. (Anatol J Cardiol 2019; 21: 305-13)

🔖

Bu Makaleye Atıf Yap

SEGIET, O. A., ROMUK, E., KOZİELSKA, E. N., WOJCIECHOWSKA, C., PIECUCH, A., WOJNICZ, R. (2019). The concentration of interleukin-33 in heart failure with reduced ejection fraction. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 6, 305–313. https://ajindex.com/articles/366677

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Braunwald E. Heart failure. JACC Heart Fail 2013; 1: 1-20
  2. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 2018; 137: e67-e492
  3. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-9
  4. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7
  5. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41
  6. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-6
  7. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the antiTNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40
  8. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-602
  9. Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9: 1006-12
  10. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009; 2: 684-91
  11. Rogala B, Glück J. The role of interleukin-33 in rhinitis. Curr Allergy Asthma Rep 2013; 13: 196-202
  12. Aoki S, Hayakawa M, Ozaki H, Takezako N, Obata H, Ibaraki N, e